Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00087256
Recruitment Status : Terminated (For scientific, logistic, and administrative reasons.)
First Posted : July 12, 2004
Last Update Posted : January 7, 2013
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
NSABP Foundation Inc

Tracking Information
First Submitted Date  ICMJE July 8, 2004
First Posted Date  ICMJE July 12, 2004
Last Update Posted Date January 7, 2013
Study Start Date  ICMJE July 2004
Actual Primary Completion Date April 2006   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 4, 2013)
To determine whether celecoxib 400 mg bid for 3 years will decrease the incidence of adenomatous polyps of the colon and rectum in participants with Stage I adenocarcinoma of the colon. [ Time Frame: 60 months ]
Original Primary Outcome Measures  ICMJE Not Provided
Change History Complete list of historical versions of study NCT00087256 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: January 4, 2013)
  • To access whether celecoxib will increase disease-free survival. [ Time Frame: 60 months ]
  • To access whether celecoxib therapy affects self-reported symptoms and health-related quality of life. [ Time Frame: 60 months ]
  • To describe the quality of life in early stage colon cancer patients. [ Time Frame: 42 months ]
  • To evaluate if the benefits from celecoxib are more pronounced in a cohort of participants whose primary colon tumors and polyps express COX-2. [ Time Frame: 60 months ]
  • To examine the expression of signaling targets such as serine/threonine kinase (AKT) extracellular signal-regulated kinase (ERK2), and endoplasmic reticulum Ca2+-ATPases in the index tumor and polyps. [ Time Frame: 60 months ]
  • To monitor the toxicity and safety of celecoxib in this population. [ Time Frame: 60 months ]
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
Official Title  ICMJE Celecoxib Polyp Prevention Trial in Participants With Resected Stage I Colon Cancer
Brief Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. It is not yet known whether celecoxib is effective in preventing polyps in patients with colon cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of celecoxib in preventing the development of polyps in patients who have undergone surgery for stage I colon cancer.

Detailed Description

OBJECTIVES:

Primary

  • Compare celecoxib vs placebo, in terms of decreasing the incidence of adenomatous polyps of the colon and rectum, in patients with resected stage I adenocarcinoma of the colon.

Secondary

  • Compare disease-free survival of patients treated with these regimens.
  • Compare the effect of these regimens on self-reported symptoms and health-related quality of life of these patients.
  • Compare the quality of life of patients treated with these regimens.
  • Compare the benefits of celecoxib in patients with primary tumors or polyps that express cyclo-oxygenase-2 (COX-2) with those that do not express COX-2.
  • Compare the expression of signaling targets such as serine/threonine AKT, extracellular signal-regulated kinase 2 (ERK2), and endoplasmic reticulum Ca+2- ATPases in the index tumor and polyps.
  • Determine the toxicity and safety of celecoxib in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to gender, tumor stage (T1 vs T2), age (≤ 49 vs 50 to 59 vs ≥ 60 years), and current aspirin use (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive oral celecoxib twice daily for 3 years.
  • Arm II: Patients receive oral placebo twice daily for 3 years. In both arms, treatment continues in the absence of unacceptable toxicity or the diagnosis of invasive colon cancer, carcinoma in situ of the colon or rectum, or a non-colon primary cancer.

Quality of life is assessed at baseline and then at 6, 12, 24, 36, and 42 months.

Patients are followed at 6 months and at 2 years.

PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 2.5 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE Colorectal Cancer
Intervention  ICMJE
  • Drug: Celecoxib
    Other Name: Celebrex
  • Other: placebo
Study Arms  ICMJE
  • Placebo Comparator: Arm 1: placebo
    one placebo capsule taken orally twice a day for 3 years
    Intervention: Drug: Celecoxib
  • Experimental: Arm 2: celecoxib
    one 400 mg capsule taken orally twice a day for 3 years
    Intervention: Other: placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: January 4, 2013)
18
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE April 2006
Actual Primary Completion Date April 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

DISEASE CHARACTERISTICS:

  • Histologically confirmed adenocarcinoma of the colon

    • Stage I disease
    • Distal border of tumor ≥ 12 cm from the anal verge
  • Tumor completely resected within the past 90 days
  • Must have undergone a preoperative or postoperative colonoscopy to the cecum (or small bowel anastomosis) within the past 90 days

    • All observed polyps must have been removed
  • Patients with a history suggestive of hereditary non-polyposis colorectal cancer (HNPCC) must have a normal microsatellite instability status by immunohistochemistry or polymerase chain reaction

    • Patients with family history of colon cancer who have not been diagnosed with HNPCC are eligible
  • No prior familial adenomatous polyposis
  • No prior invasive cancer or carcinoma in situ of the colon or rectum
  • No clinical or radiologic evidence of metastatic disease

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • Zubrod 0-1

Life expectancy

  • At least 10 years

Hematopoietic

  • Complete blood count normal
  • Platelet count normal

Hepatic

  • Aspartate aminotransferase (AST) normal
  • Bilirubin normal
  • Alkaline phosphatase normal

Renal

  • Creatinine normal

Cardiovascular

  • No active ischemic heart disease
  • No New York Heart Association class III or IV heart disease
  • No myocardial infarction within the past 6 months
  • No symptomatic arrhythmia
  • No symptomatic peripheral vascular disease or carotid disease that would preclude study participation

Pulmonary

  • No aspirin-sensitive asthma

Gastrointestinal

  • No history of inflammatory bowel disease
  • No history of upper gastrointestinal bleeding
  • No history of duodenal or gastric ulcer

Other

  • No known hypersensitivity to any COX-2 inhibitor, NSAIDs, aspirin, or sulfonamides
  • No non-colorectal malignancy within the past 5 years except carcinoma in situ of the cervix, melanoma in situ, or basal cell or squamous cell skin cancer
  • No other disease that would preclude study participation
  • No psychiatric disorders, including history of clinical depression or addictive disorders, that would preclude giving informed consent or long-term compliance
  • No rheumatologic or skeletal disorders requiring chronic NSAIDs or steroid therapy
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • Not specified

Endocrine therapy

  • Not specified

Radiotherapy

  • Not specified

Surgery

  • See Disease Characteristics

Other

  • No other concurrent investigational agents for colon cancer
  • No concurrent chronic use of other cyclo-oxygenase-2 (COX-2) inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), or salicylates (e.g., aspirin)

    • Chronic use is defined as use for more than an average of 3 days per month

      • Concurrent NSAIDs allowed for up to 10 consecutive days for temporary relief due to inflammatory syndromes, injury, or postoperative pain
    • Cardioprotective doses of aspirin (≤ 81 mg/day or 325 mg every other day) allowed
  • No concurrent fluconazole or lithium
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00087256
Other Study ID Numbers  ICMJE NSABP P-3
NSABP-P-3
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party NSABP Foundation Inc
Study Sponsor  ICMJE NSABP Foundation Inc
Collaborators  ICMJE National Cancer Institute (NCI)
Investigators  ICMJE
Principal Investigator: Norman Wolmark, MD NSABP Foundation Inc
PRS Account NSABP Foundation Inc
Verification Date January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP